BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 174 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2019. The put-call ratio across all filers is 0.44 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $6,738,000 | -24.5% | 56,823 | -12.3% | 0.02% | -5.0% |
| Q4 2021 | $8,926,000 | +5.3% | 64,771 | +6.1% | 0.02% | 0.0% |
| Q3 2021 | $8,478,000 | +6.2% | 61,034 | -25.8% | 0.02% | 0.0% |
| Q2 2021 | $7,981,000 | +47.9% | 82,213 | +4.1% | 0.02% | +33.3% |
| Q1 2021 | $5,396,000 | -21.9% | 78,942 | -2.1% | 0.02% | -21.1% |
| Q4 2020 | $6,913,000 | +61.9% | 80,658 | +22.8% | 0.02% | +26.7% |
| Q3 2020 | $4,269,000 | -5.4% | 65,669 | +6.3% | 0.02% | -11.8% |
| Q2 2020 | $4,515,000 | +123.0% | 61,750 | +3.8% | 0.02% | +54.5% |
| Q1 2020 | $2,025,000 | -12.0% | 59,515 | +40.7% | 0.01% | -8.3% |
| Q4 2019 | $2,302,000 | +248.8% | 42,289 | +167.5% | 0.01% | +200.0% |
| Q3 2019 | $660,000 | +71.0% | 15,808 | +79.3% | 0.00% | +100.0% |
| Q2 2019 | $386,000 | -16.3% | 8,818 | -1.5% | 0.00% | -33.3% |
| Q1 2019 | $461,000 | – | 8,950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |